Spero Therapeutics Secures $105 Million Royalty Financing for SP001 Development
Spero Therapeutics (NASDAQ:SPRO) has secured a non-dilutive, royalty-based financing of $105 million from HealthCare Royalty affiliates to fund its clinical pipeline. The capital will support the Phase 2 development of SP001 and is sourced through future royalties on Utebzi, an antibiotic licensed to GSK.